4.1 Article

Primary gliomatosis cerebri involving gray matter in pediatrics: a distinct entity? A multicenter study of 14 cases

Journal

CHILDS NERVOUS SYSTEM
Volume 29, Issue 4, Pages 565-571

Publisher

SPRINGER
DOI: 10.1007/s00381-012-2016-1

Keywords

Gliomatosis cerebri; Gray matter; MRI; Pediatric; Brain

Ask authors/readers for more resources

Gliomatosis cerebri (GC) is a rare neoplasm including a variety of tumors, with extremely variable evolution and heterogeneity of prognosis. It may appear either de novo or after a focal glioma, involve predominantly the white or the gray matter, and concern either pediatric or adult patients. We focused on primary GC involving exclusively gray matter in a pediatric population in order better to define the presentation and outcome of this disease. We reviewed the databases of seven Departments of Pediatric Oncology to identify pediatric cases of GC between 1990 and 2007. Patients were included if they demonstrated a diffuse infiltrative process involving gray matter in magnetic resonance imaging (MRI) and histological tissue analyses, confirming a proliferative glial disorder. Fourteen patients with a median age of 8 years were identified. Epilepsy was the main presenting symptom. Brain MRI showed a lesion of the temporal and insular cerebral cortex associated with tumoral infiltration of the thalami and the basal ganglia. Histological examination confirmed the diagnosis of high-grade glioma. Prognosis was always very gloomy in the short term, with a median survival of less than a year. This rare entity, whose prognosis is appalling whatever the treatment proposed, should be clearly identified within the heterogeneous group of GC in the same way as diffuse intrinsic pontine gliomas have been identified among brain stem tumors. Systematic biopsies appear essential to permit the molecular studies which will assist in guiding the choice of future targeted treatments.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Clinical Neurology

Science, fake news, and the naked truth

M. Vinchon

CHILDS NERVOUS SYSTEM (2023)

Article Clinical Neurology

被撤回的出版物: Confessed versus denied inflicted head injuries in infants: similarities and differences (Retracted article. See MAR, 2023)

Matthieu Vinchon, Melodie-Anne Karnoub, Nathalie Noule, Marie-Emilie Lampin

Summary: The study compared AHI cases with and without confession, finding that the confession group had more severe clinical symptoms and outcomes. While there were no significant differences in the child and caregivers' previous medical history between the two groups, the confession status might be influenced by the severity of the inflicted injuries.

CHILDS NERVOUS SYSTEM (2022)

Letter Clinical Neurology

Answer to Lynoe: Interesting data about confessions and abusive head trauma, but suboptimal analysis REPLY

Matthieu Vinchon, Melodie-Anne Karnoub, Nathalie Noule, Marie-Emilie Lampin

Summary: The authors respond to criticisms of their study's methodology by a Swedish expert. They acknowledge some limitations but maintain their conclusions, stating that the diagnosis was correct in both confession and denial groups, and denial was more difficult in severe cases.

CHILDS NERVOUS SYSTEM (2022)

Letter Oncology

Trametinib for a BRAF G469A missense mutation in a neuroblastoma unveiled by liquid biopsy

Gauthier Toutain, Victoria Min, Angelique Rome, Nicolas Andre

PEDIATRIC BLOOD & CANCER (2022)

Article Oncology

Blood-Derived Liquid Biopsies Using Foundation One® Liquid CDx for Children and Adolescents with High-Risk Malignancies: A Monocentric Experience

Fanny Cahn, Gabriel Revon-Riviere, Victoria Min, Angelique Rome, Pauline Filaine, Annick Pelletier, Sylvie Abed, Jean-Claude Gentet, Arnauld Verschuur, Nicolas Andre

Summary: This study retrospectively analyzed the feasibility and results of tumor molecular profiling using liquid biopsy in pediatric oncology patients. The results showed that this method was feasible in pediatric patients and successfully identified actionable mutations in a subset of patients.

CANCERS (2022)

Editorial Material Clinical Neurology

Abusive head trauma in Japan: editorial comment

Matthieu Vinchon

CHILDS NERVOUS SYSTEM (2022)

Retraction Clinical Neurology

撤稿声明: Retraction Note: Confessed versus denied inflicted head injuries in infants: similarities and differences (Retraction of Vol 38, Pg 147, 2022)

Matthieu Vinchon, Melodie-Anne Karnoub, Nathalie Noule, Marie-Emilie Lampin

CHILDS NERVOUS SYSTEM (2023)

Article Clinical Neurology

Unruptured cerebral arteriovenous malformation in children: Outcome in treated and untreated patients

Matthieu Vinchon, Amelie Toubol, Melodie-Anne Karnoub, Rabih Aboukais, Xavier Leclerc, Nicolas Reyns

Summary: This retrospective study evaluated the management and outcomes of URCAVM in children from 2001 to 2021. Out of 36 patients, 12 were managed by observation and 24 underwent different first-line treatments. After a mean follow-up of 63 months, 58% of the treatment group achieved complete cure, while 2 patients in the observation group experienced cerebral hemorrhage. The treatment group also had some patients with new neurological deficits, but most cases showed improvement in headache symptoms.

NEUROCHIRURGIE (2023)

Article Oncology

Mammary-analog secretory carcinoma in children: Surgery or TRK inhibitors first?

Eric Moreddu, Nicolas Andre, Romain Appay

Summary: We report two cases of pediatric mammary-analog secretory carcinoma (MASC) in which the diagnosis was challenging, but achieved by identifying the ETV6::NTRK3 fusion transcript. Both patients, a male operated on at age 8 and a female operated on at 12, are in remission 2 years after surgery. Considering the successful results of TRK inhibitor treatments in adult MASC and pediatric tumors expressing an ETV6::NTRK3 fusion, they should probably be recommended as the first-line treatment in cases with potential serious sequelae or metastatic disease that require surgery.

PEDIATRIC BLOOD & CANCER (2023)

Article Medicine, General & Internal

Retrospective National Real Life Experience of the SFCE with the Metronomic MEMMAT and MEMMAT-like Protocol

Camille Winnicki, Pierre Leblond, Franck Bourdeaut, Anne Pagnier, Gilles Paluenzela, Pascal Chastagner, Gwenaelle Duhil-De Benaze, Victoria Min, Helene Sudour-Bonnange, Catherine Piette, Natacha Entz-Werle, Sylvie Chabaud, Nicolas Andre

Summary: This study retrospectively analyzed pediatric patients with relapsed high-risk brain tumors treated with the METMAT or METMAT-like regimen. It found that this treatment approach can lead to sustained control of the tumors, with the best outcomes observed at first relapse.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Oncology

Phase I Study of a Combination of Fluvastatin and Celecoxib in Children with Relapsing/Refractory Low-Grade or High-Grade Glioma (FLUVABREX)

Pierre Leblond, Emmanuelle Tresch-Bruneel, Alicia Probst, Nadege Neant, Caroline Solas, Arthur Sterin, Thomas Boulanger, Isabelle Aerts, Cecile Faure-Conter, Anne-Isabelle Bertozzi, Pascal Chastagner, Natacha Entz-Werle, Emilie De Carli, Marie-Cecile Le Deley, Gauthier Bouche, Nicolas Andre

Summary: This study tested the repurposing of two non-anticancer drugs to provide less toxic therapeutic options for children with gliomas. The recommended phase II dose of fluvastatin in combination with celecoxib for children with gliomas is 6mg/kg/day, with a fixed daily dose of celecoxib depending on weight. This combination may be explored as a maintenance treatment in low-grade glioma patients to delay tumor recurrence.

CANCERS (2023)

Article Immunology

BNT162b2 COVID-19 Vaccines in Children, Adolescents and Young Adults with Cancer-A 1-Year Follow-Up

Caroline Donze, Victoria Min, Laetitia Ninove, Xavier de Lamballerie, Gabriel Revon Riviere, Arnauld Verschuur, Paul Saultier, Nicolas Andre

Summary: This study evaluated the adverse effects and immunological response associated with BNT162B2 vaccination in children and young adults with cancer. The results showed that most patients had an increase in antibody levels and the vaccine was effective in neutralizing the SARS-CoV-2 virus. In addition, COVID-19 infections after vaccination were mild in all cases.

VACCINES (2023)

Letter Biochemistry & Molecular Biology

AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trial

Birgit Geoerger, Xavier Paoletti, Francisco Bautista, Susanne A. Gatz, Lynley V. Marshall, Nicolas Andre, Pablo Berlanga, Stephane Ducassou, Claudia Pasqualini, Michela Casanova, C. Michel Zwaan, Karsten Nysom, Jonathan Rubino, Delphine Vuillier-Le Goff, Baptiste Archambaud, Samuel Abbou, Gudrun Schleiermacher, Christelle Dufour, Patricia Blanc, Natalie Hoog-Labouret, Agnes Buzyn, Gilles Vassal

NATURE MEDICINE (2023)

No Data Available